FY 2026 marked a significant inflection point for Aspen as the Group delivered strong normalised earnings growth, improved profitability across both Commercial Pharmaceuticals and Manufacturing, and successfully completed the APAC divestment.
FY 2026 marked a significant inflection point for Aspen as the Group delivered strong normalised earnings growth, improved profitability across both Commercial Pharmaceuticals and Manufacturing, and successfully completed the APAC divestment.
Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.